CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: January-27-14
Credit Expiration Date: January-27-15


Mikkael A. Sekeres, MD, MS
Professor of Medicine
Director, Leukemia Program
Cleveland Clinic
Taussig Cancer Institute
Cleveland, OH

CCME Reviewer:
Victor B. Hatcher, PhD
Professor of Medicine and Biochemistry
Associate Dean, CME and Research
Albert Einstein College of Medicine
Director of the Office of Research and Sponsored Programs
Director of CME Montefiore Medical Center
Bronx, NY

Credit Hours

Physicians: 0.5 AMA PRA Category 1 CreditTM



Program Description

A CME-certified online interactive newsletter featuring meeting highlights from ASH 2013 about acute myeloid leukemia (AML).

Clinical advances in the management of AML are occurring at a rapid rate as the treatment approach shifts from intensity of therapy to specificity of therapy. However, optimal utilization of genetic and molecular information for classification and treatment of AML is not yet known and clinicians find it challenging to stay abreast of novel advances in AML prognosis and treatment.

The goal of this CME-certified activity is to increase knowledge among hematology-oncology clinicians with regard to new evidence-based practices in molecular- and genetically-guided therapies, thereby enhancing their ability to implement these practices and improve patient care and outcomes.

Program Developer/Facilitator

This activity is jointly provided by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.

Target Audience

This activity is intended for hematologists, oncologists, and other clinicians involved in the management of AML.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Summarize cutting-edge research in AML presented at ASH 2013, including key findings of studies on novel genetic and molecular targets, agents and treatment strategies.
  2. Identify genetic and molecular markers that are associated with good or poor prognosis in MDS, AML, and therapy-related AML.
  3. Identify novel agents for the treatment of de novo relapsed and refractory AML and MDS.


The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present. Albert Einstein College of Medicine and MCM Education staff have no conflicts of interest with commercial interests related directly or indirectly to this educational activity.

Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product not yet approved for use in the United States.

Dr. Sekeres discloses that he has served as a consultant for Celgene and Amgen.

The Staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine and Montefiore Medical Center have no relevant financial disclosures.
Dr. Hatcher has no relevant financial disclosures.
Don Harting (Medical Writer) has no relevant financial disclosures.
Kathleen Hines (MCM Education Editorial Director) has no relevant financial disclosures.

Credit Statements

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine, Montefiore Medical Center and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Albert Einstein College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit is awarded to participants who score 75% or better on the post-test.

This activity will take approximately 30 minutes to complete.

Commercial Support Statements

Supported by an independent educational grant from Boehringer Ingelheim, Inc.


There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.

  1. Review the intended audience, learning objectives, and author disclosures.
  2. Study the educational content online. Be sure to review both written and audio/slide content.
  3. Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
  4. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee



Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, and MCM Education.

The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, or Boehringer Ingelheim, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu